Jianqiang Li1
Carlotta Bollati1
Gilda Aiello2
Martina Bartolomei1
Fabrizio Rivardo3
Giovanna Boschin1
Anna Arnoldi1
Carmen Lammi1*- 1Department of Pharmaceutical Sciences, University of Milan, Milan, Italy
- 2Department of Human Science and Quality of Life Promotion, Telematic University San Raffaele, Rome, Italy
- 3A. Costantino & C. Spa, Favria, Italy
The objective of the study was the evaluation of the potential pleiotropic effect of a commercial casein hydrolysate (CH). After an analysis of the composition, the BIOPEP-UWM database suggested that these peptides contained numerous sequences with potential inhibitory activities on angiotensin converting enzyme (ACE) and dipeptidyl-peptidase IV (DPP-IV). The anti-diabetic and anti-hypertensive effects of these peptides were thus assessed using either cell-free or cell-based assays. In the cell-free system, CH displayed inhibitory properties against DPP-IV (IC50 value equal to 0.38 ± 0.01 mg/mL) and ACE (IC50 value equal to 0.39 ± 0.01 mg/mL). Further, CH reduced the DPP-IV and ACE activities expressed by human intestinal Caco-2 cells by 61.10 ± 1.70% and 76.90 ± 4.47%, respectively, versus untreated cells, after 6 h of treatment at the concentration of 5 mg/mL. This first demonstration of the multifunctional behavior of this material suggests that it may become an anti-diabetic and/or anti-hypertensive ingredient to be included in the formulation of different functional food or nutraceutics.
1. Introduction
Type II diabetes is a chronic disease, which affects millions of people worldwide: the inadequate secretion of insulin by β-cells and/or insulin resistance in tissues are its main characteristics (1). Dipeptidyl-peptidase IV (DPP-IV) is known for its inactivation of two intestinal hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which possess potent insulin-secretory activity, and consequently lower prandial plasma glucose (1). Due to the short half-life (< 2 min) of the degradation of GLP-1 and GIP by DPP-IV, the inhibition of DPP-IV is an attractive therapeutic strategy to maintain the insulinotropic activity of GLP-1 and GIP, resulting in an improved homeostasis of glucose in type II diabetes (2). Interestingly, a number of studies indicate that most people with diabetes will eventually develop hypertension and other blood circulation complications, especially showing a close association between Type II diabetes and hypertension (3, 4). There are many factors associated with the development of hypertension, one of them is related to the conversion of angiotensin I, an active decapeptide, into angiotensin II, a potent vasoconstrictor octapeptide, by the angiotensin-converting enzyme (ACE) system. Meanwhile, the inactivation of bradykinin, which shows a significant vasodilator activity, is caused by ACE. Therefore, inhibition of ACE is considered an effective treatment for lowering blood pressure in hypertensive subjects (5).
Inhibitors of DPP-IV and/or ACE are regularly applied in therapy to lower morbidity and mortality of patients with type II diabetes and/or hypertension. Synthetic inhibitors of DPP-IV and/or ACE are the first-line option for the treatment of these events (6), however, inevitable and evitable side effects of them, such as coughing, skin rashes, taste disturbances, angioedema, hyperkalaemia (ACE inhibitors) (7, 8), and nasopharyngitis, headache, diarrhea, joint pain, urinary tract infection (DPP-IV inhibitors) (9, 10), highlight the importance of developing new natural, innovative side-effect free compounds to prevent and/or alleviate diabetes and hypertension. Over the past few decades, many evidences have underlined that protein hydrolysates obtained from both plant (soybean, pea, rice bran, lupin, wheat, and many others) and/or animal (milk, egg yolk, beef, pork, chicken, sardine, salmon, and many others) foods may be useful for the prevention of these pathologies and several food derived peptides with potent DPP-IV-inhibitory and/or ACE-inhibitory activities have been successfully identified and characterized (11–16). These peptides are encrypted within the protein sequences and are released by the hydrolysis (17). They may be obtained with digestive enzymes (i.e., pepsin and trypsin), mimicking the action of in vivo gastrointestinal digestion, or produced using plant (i.e., bromelin) or microbial (i.e., Alcalase® and Flavourzyme®) food grade enzymes, as well as during some food manufacture processes, such fermentation (18, 19).
It has been clearly demonstrated (20) that milk protein derived peptides possess different biological properties, including antimicrobial (21), antioxidant (22), anti-inflammatory (23), antithrombotic, hypocholesterolemic (24) and anti-hypertensive (22) activities useful for cardiovascular risk prevention. Moreover, they are active in preventing nervous system and bone diseases (25, 26). Most of these bioactive peptides are generated from the degradation of casein, which makes up around 80% of the protein in cow milk and it is composed by α-, β- and κ-caseins (27).
In light with these considerations, this study had the goal of assessing the pleiotropic health-promoting effects of a commercial casein hydrolysate (CH), obtained by an industrial process. Since casein is an excellent source of biologically active peptides, it was hypothesized that this industrial product may possess a dual biological behavior, including DPP-IV-inhibitory and/or ACE-inhibitory activity. The first objective of the study was the characterization of the chemical composition of CH for identifying sequences that may be responsible for its biological activity. The second aim was the evaluation of the potential anti-diabetic and hypotensive effects of CH by measuring its inhibitory activities toward both DPP-IV and ACE. This was achieved by using either cell-free tests or cell assays based on human intestinal Caco-2 cells. Finally, the same experimental procedures were employed to evaluate the activities of the fraction with a molecular weight lower than 3 kDa [CH (F3)].
2. Results
2.1. Peptidomic characterization of CH
The peptide composition of CH was analyzed by using HPLC-ESI-MS/MS. Figure 1 displays the total ion current (TIC) of the MS/MS of eluted peptides. The percentage of peptides with MW > 3 kDa was 37.95%, whereas the percentage of peptides with MW < 3 kDa was 62.05%. In addition, CH was ultra-filtered using a 3 kDa cutoff obtaining the low molecular peptide fraction, named CH (F3), which was investigated in parallel with total CH sample.
Figure 1. The total ion chromatogram (TIC) of CH was obtained injected 1 μg/μL.
As shown in Table 1, 37 identified peptides belong to caseins: in particular, 18 belong to α-S1-casein, whereas 19 belong to β-casein. The lengths of those peptides range from 6 to 18 amino acids, whereas their isoelectric points (pI) and hydrophobicity range from 2.87 to 11.13 (pH) and from +4.41 to +23.87 (kcal×mol−1), respectively. Additionally, as reported by the BIOPEP-UWM database (,1 accessed on 16 Feb 2023), all peptides contain one or more motives including known sequences of either ACE or DPP-IV inhibitors.
Table 1. Identified peptides belonging to caseins, with inhibitory activity against both angiotensin converting enzyme (ACE) and dipeptidyl peptidase-IV (DPP-IV).
2.2. Biochemical study of the DPP-IV and ACE inhibitory activities of CH
2.2.1. The inhibition of in vitro DPP-IV activity by CH and CH (F3)
The assessment of CH ability to regulate the DPP-IV activity was carried out using the purified recombinant DPP-IV enzyme. Results clearly demonstrated that CH decreased the DPP-IV activity in vitro with a dose–response trend in the concentration range of 0.1, 0.5, 1.0, and 2.5 mg/mL, displaying an IC50 value of 0.38 ± 0.01 mg/mL (Figure 2A). To further confirm this inhibitory activity, the experiments were carried out on the low molecular weight fraction (<3 kDa), named CH (F3), in the same experimental conditions (Figure 2B). This low molecular weight fraction dropped the DPP-IV activity in vitro too, showing a dose–response trend and an IC50 value of 0.31 ± 0.05 mg/mL (Figure 2B). A comparison of the IC50 value of the total CH hydrolysate with that of CH (F3) suggests that short-sized peptides are mainly responsible for the DPP-IV inhibitory activity (Table 2).
Figure 2. Examining the in vitro inhibitory properties of CH (A) and CH (F3) (B) against human recombinant dipeptidyl peptidase-IV (DPP-IV), obtained using cell-free assay. The bars show the mean ± s.d. of three independent experiments carried out in duplicate. Different lowercase letters indicate a significant difference (p < 0.05) between different concentrations. C (H2O): control cells.
Table 2. IC50 values obtained testing CH and its fractions (molecular weight: < 3 kDa) against in vitro dipeptidyl peptidase-IV (DPP-IV) and angiotensin converting enzyme (ACE).
2.2.2. Effect of CH and CH (F3) on in vitro ACE activity
The inhibitory effects of CH on the in vitro ACE activity were tested at 0.08–1.0 mg/mL concentration range. As shown in Figure 3A, CH efficiently inhibited the in vitro ACE activity with a dose–response trend and a calculated IC50 value of 0.39 ± 0.01 mg/mL, whereas CH (F3) displayed an IC50 value of 0.24 ± 0.01 mg/mL (Figure 3B). Interestingly, the inhibitory activities of CH (F3) were slightly higher than that of CH at the same concentrations, indicating that short peptides are probably responsible for the in vitro ACE inhibitory activity.
Figure 3. The inhibitory effects of CH (A) and CH (F3) (B) on angiotensin converting enzyme (ACE) were evaluated in vitro, using cell-free assay. The bars representing the mean ± s.d. of three independent experiments performed in duplicate. Different lowercase letters indicate a significant difference (p < 0.05) between different concentrations. C (H2O): control cells.
Finally, Table 2 summarizes a comparison of the in vitro IC50 values of CH and CH (F3) against DPP-IV and ACE.
2.3. The examination of DPP-IV and ACE inhibition by CH and CH (F3) at cellular level
2.3.1. CH and CH (F3) inhibit the DPP-IV activity expressed by Caco-2 cells
No effects of CH and CH (F3) on human intestinal Caco-2 cells viability was observed by performing MTT after 48-h treatment within the concentration range of 1.0–5.0 mg/mL compared with control cells (C) (Figure 4), suggesting that both samples are safe in the range of doses tested.
Figure 4. Effect of CH (A) and CH (F3) (B) on the Caco-2 cells viability. Data represents the mean ± s.d. of four independent experiments carried out in duplicate. ns: no significance, C: control cells (H2O).
The CH inhibitory effect of DPP-IV expressed on Caco-2 cellular membranes was then investigated. In detail, the inhibitory effect of CH and CH (F3) on cellular DPP-IV activity was measured in a kinetic mode after 1, 3, and 6 h of incubation with CH or CH (F3) in the range of concentrations 1.0–5.0 mg/mL. As shown in Figure 5A, CH dropped the cellular DPP-IV activity by 28.20 ± 7.11%, 45.11 ± 5.38%, and 47.04 ± 8.73% at 1.0, 2.5 and 5 mg/mL, respectively (after 1 h), and by 23.46 ± 5.79%, 41.73 ± 2.88% and 51.68 ± 4.71% at the same concentrations (after 3 h). However, the maximal inhibition of cellular DPP-IV activity was observed after 6 h (Figures 5A,B), when CH inhibited the cellular enzyme activity by 29.23 ± 9.98%, 57.26 ± 2.69%, and 61.10 ± 1.70% at 1.0, 2.5 and 5 mg/mL, respectively, compared with untreated cells, displaying a dose–response trend and confirming the in vitro results.
Figure 5. The effect of CH (A) and CH (F3) (B) on cellular dipeptidyl peptidase-IV (DPP-IV) activity was determined, and the mean ± s.d. of four independent experiments performed in triplicate are displayed as data points. Different lowercase letters indicate a significant difference (p < 0.05) between different concentrations. ns: no significance; C (H2O): control cells.
In parallel, the evaluation of CH (F3) inhibitory activity of cellular DPP-IV was carried. Notably, CH (F3) reduced the cellular DPP-IV activity by 23.55 ± 4.31%, 43.82 ± 3.98%, and 55.35 ± 2.55% at 1.0, 2.5 and 5 mg/mL (1 h), respectively, and by 11.63 ± 7.27%, 43.50 ± 3.59%, and 54.07 ± 1.87% at 3 h (Figure 5C). In line with CH, the best inhibition of cellular DPP-IV activity by CH (F3) was detected at 6 h (Figures 5C,D), when it dropped the cellular activity by 11.54 ± 5.39%, 51.22 ± 8.74%, and 60.53 ± 6.68% at 1.0, 2.5, and 5 mg/mL, respectively, versus untreated cells.
2.3.2. CH and CH (F3) inhibit ACE activity expressed by Caco-2 cells
The CH inhibitory effect on the ACE expressed on the membranes of Caco-2 cells was evaluated treating cells with CH at 1.0–5.0 mg/mL for 6 h. Results indicated that CH inhibited the cellular ACE activity with a dose–response manner, reducing the enzyme activity by 25.04 ± 0.49%, 52.36 ± 3.53%, 56.10 ± 3.78%, and 76.90 ± 4.47%, respectively, at 0.1, 0.5, 1.0 and 5.0 mg/mL (Figure 6A). Meanwhile, CH (F3) is able to decrease the cellular ACE activity by 31.42 ± 11.19%, 50.75 ± 8.75%, 63.63 ± 6.08%, and 81.39 ± 5.05% at 0.1, 0.5, 1.0, and 5.0 mg/mL after 6 h, respectively (Figure 6B).
Figure 6. Evaluation of the inhibitory effect of CH (A) and CH (F3) (B) on angiotensin converting enzyme (ACE) expressed on Caco-2 cells membranes. Bars represent the mean ± s.d. of three independent experiments in triplicate. Different lowercase letters indicate a significant difference (p < 0.05) between different concentrations. ns: no significance; C (H2O): control cells.
3. Discussion
Undoubtedly, casein is among the most studied sources of bioactive peptides with health promoting activities. Indeed, several literature evidences report that casein acts as a precursor of a diversity of bioactive peptides with anti-hypertensive, immunological, antioxidant, antithrombotic and anti-diabetic effects (28–30). In this context, the ACE-inhibitory activity was the most investigated, and numerous ACE-inhibitory peptides have been identified, for instance, VPP (31), IPP (32), NMAINPSKENLCSTFCK (33), RYPSYG and DERF (34). In addition, also DPP-IV-inhibitory peptides have also been identified from casein and characterized, such as LPQNIPPL (35) and VPYPQ (36).
In this panorama, the main limitation of most previous studies on casein hydrolysate consists on the fact that the characterization of DPP-IV or ACE inhibitory activities has been carried out independently without taking into account that the same hydrolysate may be endowed with a multifunctional behavior exerting, therefore, both activities. Moreover, great part of published papers are based exclusively on cell-free assays (i.e., pure enzyme inhibition), whereas a main peculiarity of the present study is that the in vitro tests were implemented and substantiated by cellular assays that permitted either to get a deeper insight in the mechanism of action or to contextually consider other relevant issues, such as metabolism (this is particularly true while employing Caco-2 cells).
Overall, our findings suggested that CH is able to modulate the DPP-IV and ACE activities both in cell-free and cell-based conditions. More in details, CH displayed potent inhibitory properties against DPP-IV (IC50 value of 0.38 ± 0.01 mg/mL) and ACE (IC50 value of 0.39 ± 0.01 mg/mL) in cell-free condition, respectively. Furthermore, a comparison of the IC50 values of complete hydrolysate with those of the low molecular weight fraction (<3 kDa) (Table 2), showed that medium and short-sized peptides, which account for about two thirds of the hydrolysate (62.05%), are mainly responsible of the observed biological activities.
Literature suggests that a camel total casein hydrolysate is less efficient than CH in reducing the ACE activity being its effect not observed up to 0.6 mg/mL. Whereas, the <3 kDa fraction of the same material displays an IC50 equal to 91 ± 20 μg/mL (37). In addition, the IC50 values of a thermolysin casein hydrolysate was 45–83 μg/mL (38). As regards the DPP-IV inhibitory activity, previous evidences suggest that casein hydrolysates showed IC50 values in the range 0.88–1.1 mg/mL (39), suggesting that CH is slightly more active. In addition, as reported by Zhang et al., using different proteases, casein proteins released peptides that determined the 50% of DPP-IV inhibition at 1.25 μg/mL, clearly suggesting that CH is more active (40). Notably, recent evidences suggest that both soybean hydrolysate and pea hydrolysate inhibit DPP-IV and ACE activity with a dose–response trend and IC50 values equal to 1.15 ± 0.004 and 1.33 ± 0.004 mg/mL, and 0.33 ± 0.01 and 0.61 ± 0.05 mg/mL, respectively (11).
In principle, the bioactivity of a food derived hydrolysate depends strictly on its total composition, including inactive and active species and possible synergistic or antagonist effects (41, 42). In light with this observation, Table 1 reveals that all the major identified peptides derived from CH included at least one motif with established DPP-IV and ACE inhibitory activity, which clarifies the reason why this peptide mixture is effective against both targets. Being the composition of casein hydrolysate naturally heterogeneous, it is feasible to consider that some peptides may be active against one of the two target, but we cannot exclude that some specific peptides may be contemporary endowed by the dual ability to target both ACE and DPP-IV. In addition, some peptides with post-translational modifications were also identified. Notably, it was observed that peptide VPNSAEER displays a phosphorylation on serine residue in position 4, whereas 6 different peptides (IPNPIGSENSEKTTMP, KEPMIGVN, SDIPNPIGSENSEKTTMP, EMPFPKYP, EMPFPKYPVEP, and MPFPKYPVEP) contain within their sequences oxidized methionine residue.
These results are in line with a previous work which focused on two commercially available soybean (SH) and pea (PH) protein hydrolysates (11). In particular, as regards the ACE inhibitory activity, CH displayed comparable IC50 values with those obtained of both SH and PH, whereas as regards DPP-IV activity, CH hydrolysates is about 3.5-fold more potent than both SH and PH (11).
DPP-IV and ACE are vital membrane peptidases expressed physiologically by many tissues, such as the intestine (43, 44). As a matter of fact, human intestinal Caco-2 cells offer a dependable model that has already been established and confirmed for the investigation of peptides possessing DPP-IV or ACE inhibitory characteristics (45–47). Our findings indicated that CH maintains its ability to modulate the activity of both DPP-IV and ACE on Caco-2 cells, even though both hydrolysates are active in the range of concentration between 0.1 and 5 mg/mL as a function of the time (Figure 4A). In particular, CH inhibits both enzymes activity by 61.10 ± 1.70% and 76.90 ± 4.47% at the concentration of 5 mg/mL after 6 h of treatment (Figures 4,5), versus untreated cells, respectively, indicating that CH is less active in cell-based than in cell-free conditions. Similar results have been previously obtained on SH, PH, and peptic and tryptic hydrolysates of Arthrospira platensis (Spirulina) and Chlorella pyrenoidosa proteins, respectively (11, 45, 46, 48, 49). Also in these cases, the tested hydrolysates showed greater activity in cell-free assays than in cell-based assays. More in details, PH and SH inhibited the cellular DPP-IV activity by 53.6 ± 2.3% and 48.69 ± 7.29%, respectively, and the cellular ACE activity by 82.3 ± 4.2% and 74.6 ± 4.9%, respectively, at 5 mg/mL after 3 h (11). In addition, C. pyrenoidosa hydrolysates obtained using pepsin (CP) and trypsin (CT) inhibited the cellular ACE activity by 61.5 ± 7.7% and 69.9 ± 0.8%, respectively, at 5 mg/mL. When tested at the same concentration, they reduced the cellular DPP-IV activity by 38.4 and 42.5%, respectively (45).
This discrepancy in efficacy may be explained by the metabolic capabilities of Caco-2 cells, which express active proteases and peptidases that can actively metabolize peptides and impact their bioactivity (45). Thus, the intestine performs a dynamic function, not only in the process of vital nutrient absorption but also in actively modulating the physicochemical and biological profiles of food protein hydrolysates. Moreover, the peptides composition of CH here investigated results in line with a recent research dealing with the identification of novel casein-derived bioactive peptides and their potential (ACE)-inhibitory, antioxidant, and DPP-IV inhibitory activity when casein were fermented with Lactobacillus helveticus (50). Some of the identified peptides, i.e., DIPNPIGSE, EDVPSER, FPKYPVE are common to those generated by the fermentation.
4. Conclusion
For the first time, we have characterized the multifunctional behavior of a commercial casein hydrolysate, demonstrating its dual inhibitory properties on DPP-IV and ACE, using both cell-free and cell-based assays. Indeed, the active intestinal peptidases, which are expressed on cellular membrane, modulate peptide profile without impair their pleotropic activity. Hence, our findings constitute a significant foundation for future investigation of CH by in vivo and clinical studies for confirming its multifunctional and pleotropic behavior. With its ability to confer both hypotensive and antidiabetic benefits, CH may be a highly promising ingredient for use in the development of functional foods and dietary supplements aimed at preventing cardiovascular disease and metabolic syndrome.
5. Materials and methods
5.1. Reagents
Dulbecco’s modified Eagle’s medium (DMEM), L-glutamine, fetal bovine serum (FBS), phosphate buffered saline (PBS), penicillin/streptomycin and 96-well plates were purchased from Euroclone (Milan, Italy). Acetonitrile (ACN), formic acid, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), sitagliptin, Gly-Pro-amido-4-methylcoumarin hydrobromide (Gly-Pro-AMC) and ACE from porcine kidney were from Sigma-Aldrich (St. Louis, MO, United States). ACE1 Activity Assay Kits come from Biovision (Milpitas Blvd., Milpitias, CA, United States). The DPP-IV inhibitor screening assay kit was bought from Cayman Chemical (Michigan, United States). Caco-2 cells were obtained from INSERM (Paris, France). Casein hydrolysates (CH), which is spray dried samples from the production process, was supplied by A. Costantino S.R.L. (Italy). (Casein hydrolysate sport/health batch 218F0004, 100 g). Casein hydrolysates (CH), which is spray dried samples from the production process, was supplied by A. Costantino S.R.L. (Italy). (Casein hydrolysate sport/health batch 218F0004, 100 g).
5.2. Ultrafiltration of CH
Prior to evaluating biological activity, CH was ultra-filtered using a 3 kDa cutoff on a Millipore ultrafiltration system (Millipore, Bedford, MA, United States). The peptide solution obtained was lyophilized (lyophilizer LIO5P, Cinquepascal S.r.l., Milan, Italy) for further analyzes after the storage temperature–80°C.
5.3. Mass spectrometry analysis
Samples were dissolved with 50 μL of a solution made of 1% acetonitrile (ACN) and 0.1% formic acid in distilled H2O. All samples were analyzed at UNITECH OMICs (University of Milan, Italy) using: Dionex Ultimate 3000 nano-LC system (Sunnyvale CA, United States) connected to Orbitrap Fusion™ Tribrid™ Mass Spectrometer (Thermo Scientific, Bremen, Germany) equipped with a nanoelectrospray ion source. Peptide mixtures were pre-concentrated onto an Acclaim PepMap 100–100 μm × 2 cm C18 (Thermo Scientific) and separated on EASY-Spray column ES900, 25 cm x 75 μm ID packed with Thermo Scientific Acclaim PepMap RSLC C18, 3 μm, 100 Å using mobile phase A (0.1% formic acid in distilled H2O) and mobile phase B (0.1% formic acid in acetonitrile 20/80, v/v) at a flow rate of 0.300 μL/min. The following gradient profile was used: 0 min, 4% B; 3 min, 4% B; 103 min, 28% B; 113 min, 95% B; 120 min, 4% B; 126 min, 95% B; 135 min, 4%B; 138 min, 95% B; 144 min, 4% B. The temperature was set to 35°C and the sample were injected in triplicates. MS spectra were collected over an m/z range of 375–1500 Da at 120,000 resolutions (m/z 200), operating in the data-dependent mode, cycle time of 3 s between masters scans. HCD was performed with collision energy set at 35 eV. Polarity: positive. MS data were analyzed by Proteome Discoverer 2.5 by using Bos taurus (sp_incl_isoforms TaxID = 9913_and_subtaxonomies) (v2022-12-14) without any specific enzymatic cut. Oxidation of methionine and acetylation at the protein N-terminus were specified as variable modifications.
5.4. Characterization of the inhibitory effects of CH on DPP-IV and ACE through biochemical assays
5.4.1. In vitro assessment of DPP-IV-inhibitory activity
The in vitro assessment of DPP-IV-inhibitory activity was performed following the manufacturer instructions (DPP-IV inhibitor screening assay kit–Cayman Chemical) and previously reported methods (47, 48). The experiments were carried out in triplicate in a half–area 96 well solid plate (white). Each reaction (50 μL) was prepared adding the reagents in the following order in a microcentrifuge tube: 1 X assay buffer [20 mM Tris–HCl, pH 8.0, containing 100 mM NaCl, and 1 mM EDTA] (30 μL), CH and CH (F3) at final concentration range of 0.01–2.0 mg/mL (10 μL) or vehicle (10 μL of distilled H2O) and finally the DPP-IV enzyme (10 μL). Subsequently, the samples were mixed and 50 μL of each reaction were transferred in each well of the plate. The reactions were started by adding 50 μL of substrate solution to each well and incubated at 37°C for 30 min. Fluorescence signals were measured using the Synergy H1 fluorescent plate reader from Biotek (excitation and emission wavelengths 360 and 465 nm, respectively).
5.4.2. In vitro assessment of ACE-inhibitory activity
The ACE-inhibitory activity of the CH was evaluated following previously reported methods (51, 52) and tested by measuring with HPLC the formation of hippuric acid (HA) from hippuryl-histidyl-leucine (HHL), used as mimic substrate for ACE. Tests were performed in 100 mM Tris-HCOOH, 300 mM NaCl pH 8.3 buffer, and using ACE from porcine kidney (Sigma-Aldrich, Milan, Italy). CH hydrolysate was tested at 0.08, 0.17, 0.35, 0.7 and 1.0 mg/mL.
5.5. Assessment of the inhibitory effects of CH on DPP-IV and ACE activities using cellular assays
5.5.1. Culture of Caco-2 cells
Caco-2 cells were routinely sub-cultured at 50% density and maintained at 37°C in 5% CO2 atmosphere in Dulbecco’s modified Eagle’s medium (DMEM) containing 25 mM of glucose, 3.7 g/L of NaHCO3, 4 mM of stable L-glutamine, 1% nonessential amino acids, 100 U/L of penicillin, and 100 μg/L of streptomycin (complete medium), supplemented with 10% heat-inactivated fetal bovine serum (FBS), as reported elsewhere (53). The cells were used for no more than 20 passages.
5.5.2. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
A total of 3 × 104 Caco-2 cells/well were seeded in 96-well plates and, the day after, they were treated with 1.0, 2.5, and 5 mg/mL of CH or CH (F3) or vehicle (distilled H2O) in complete growth media for 48 h at 37°C under 5% CO2 atmosphere. Subsequently, the treatment solvent was aspirated and 100 μL/well of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) filtered solution added. After 2 h of incubation at 37°C under 5% CO2 atmosphere, 0.5 mg/mL solution was aspirated and 100 μL/well of the lysis buffer (8 mM HCl + 0.5% NP-40 in DMSO) added. After 10 min of slow shaking, the absorbance at 575 nm was read on the Synergy H1 fluorescence plate reader (Biotek, Bad Friedrichshall, Germany) as reported in previously work (11).
5.5.3. Assessment of the inhibitory activity of CH on cellular DPP-IV activity
Caco-2 cells were seeded on black 96-well plates with clear bottoms at a density of 3 × 104 cells/well. After 1 day, cells were treated with 1.0, 2.5 and 5.0 mg/mL of CH or CH (F3) (100 μL/well) for 1, 3 and 6 h; at the end of the incubation, cells were washed once with 100 μL of PBS, then, 50 μL of Gly-Pro-AMC substrate at concentrations of 25 μM in PBS were added and the fluorescence signals (excitation/emission wavelengths 350/450 nm) in each well were measured using a Synergy H1 (BioTek Instruments, Winooski, VT, USA) every 1 min for 10 min.
5.5.4. Assessment of the inhibitory activity of CH on cellular ACE1 activity
The inhibitory activity of CH on cellular ACE1 activity was evaluated following a previously reported method (54). Caco-2 cells were seeded on 96-well plates at a density of 3 × 104 cells/well for 24 h. The following day, cells were treated with 100 μL/well of CH or CH (F3) (at the final concentrations of 0.1–5.0 mg/mL) or vehicle in growth medium for 6 h at 37°C, then cells were scraped in 30 μL of ice-cold ACE1 lysis buffer and transferred in an ice-cold eppendorf tube. After centrifugation at 13,300 g for 15 min at 4°C, the supernatant was recovered and transferred into a new ice-cold tube. Total proteins were quantified by Bradford method, and 2 μg of total proteins (the equivalent of 2 μL) were added to 18 μL of ACE1 lysis buffer in each well in a black 96-well plates with clear bottoms. For the background control, 20 μL of ACE1 lysis buffer were added to 20 μL of ACE1 assay buffer. Subsequently, 20 μL of 4% of ACE1 substrate (prepared in assay buffer) was added in each well except the background one and the fluorescence (Ex/Em 330/430 nm) was measured in a kinetic mode for 10 min at 37°C.
5.6. Statistical analysis
The statistical analysis was conducted through one-way ANOVA (GraphPad Prism 9.1, GraphPad Software, La Jolla, CA, United States), and Tukey’s multiple comparison test was used for post-hoc analysis. The assays were performed independently at least four times, and each experiment was conducted in triplicate. The data were expressed as mean ± standard deviation (s.d.), and statistical significance was set at p < 0.05.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
CL, JL, CB, GA, MB, GB, and FR: experiments. CL: discussion of the results. CL and JL: manuscript writing (original draft). CL and AA: manuscript editing. All authors have read and agreed to the published version of the manuscript.
Funding
This research and the APC were funded by A. Costantino & C. Spa.
Acknowledgments
The authors gratefully acknowledge the financial support from the China Scholarship Council for a fellowship to JL. We are indebted to Carlo Sirtori Foundation (Milan, Italy) for having provided part of equipment used in this experimentation.
Conflict of interest
FR was employed by A. Costantino & C. Spa which had the following involvement in the study: provided the calculated molecular weight distribution of peptide samples.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Footnotes
References
1. Eizirik, DL, Pasquali, L, and Cnop, M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nature reviews. Endocrinology. (2020) 16:349–62. doi: 10.1038/s41574-020-0355-7
2. Holst, JJ, and Deacon, CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. (1998) 47:1663–70. doi: 10.2337/diabetes.47.11.1663
3. Schutta, MH. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr. (2007) 2:124–30. doi: 10.1111/j.1559-4564.2007.06368.x
4. De Boer, IH, Bangalore, S, Benetos, A, Davis, AM, Michos, ED, Muntner, P, et al. Diabetes and hypertension: a position statement by the American diabetes association. Diabetes Care. (2017) 40:1273–84. doi: 10.2337/dci17-0026
5. Bernstein, KE, Khan, Z, Giani, JF, Cao, DY, Bernstein, EA, and Shen, XZ. Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol. (2018) 14:325–36. doi: 10.1038/nrneph.2018.15
6. Juillerat-Jeanneret, L. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? J Med Chem. (2014) 57:2197–212. doi: 10.1021/jm400658e
7. Sica, DA. Angiotensin-converting enzyme inhibitors’ side effects–physiologic and non-physiologic considerations. J Clin Hypertens. (2005) 6:410–6. doi: 10.1016/B978-0-7216-0258-5.50155-1
8. Kostis, WJ, Shetty, M, Chowdhury, YS, and Kostis, JB. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. (2017) 20:55. doi: 10.1007/s11906-018-0859-x
9. Gallwitz, B. Clinical use of DPP-4 inhibitors. Front Endocrinol. (2019) 10:389. doi: 10.3389/fendo.2019.00389
10. Kshirsagar, AD, Aggarwal, AS, Harle, UN, and Deshpande, AD. DPP IV inhibitors: Successes, failures and future prospects. Diabetes Metab Syndr. (2011) 5:105–12. doi: 10.1016/j.dsx.2012.02.017
11. Bollati, C, Xu, R, Boschin, G, Bartolomei, M, Rivardo, F, Li, J, et al. Integrated evaluation of the multifunctional DPP-IV and ACE inhibitory effect of soybean and pea protein Hydrolysates. Nutrients. (2022) 14:2379. doi: 10.3390/nu14122379
12. Murray, B, and FitzGerald, R. Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry bioactivity and production. Curr Pharm Des. (2007) 13:773–91. doi: 10.2174/138161207780363068
13. Lee, SY, and Hur, SJ. Antihypertensive peptides from animal products, marine organisms, and plants. Food Chem. (2017) 228:506–17. doi: 10.1016/j.foodchem.2017.02.039
14. Zambrowicz, A, Pokora, M, Setner, B, Dąbrowska, A, Szołtysik, M, Babij, K, et al. Multifunctional peptides derived from an egg yolk protein hydrolysate: isolation and characterization. Amino Acids. (2015) 47:369–80. doi: 10.1007/s00726-014-1869-x
15. Guang, C, and Phillips, RD. Plant food-derived angiotensin i converting enzyme inhibitory peptides. J Agric Food Chem. (2009) 57:5113–20. doi: 10.1021/jf900494d
16. Liu, R, Cheng, J, and Wu, H. Discovery of food-derived dipeptidyl peptidase IV inhibitory peptides: a review. Int J Mol Sci. (2019) 20:463. doi: 10.3390/ijms20030463
17. Bhandari, D, Rafiq, S, Gat, Y, Gat, P, Waghmare, R, and Kumar, V. A review on bioactive peptides: physiological functions, bioavailability and safety. Int J Pept Res Ther. (2020) 26:139–50. doi: 10.1007/s10989-019-09823-5
18. Hernández-Ledesma, B, Del Mar, CM, and Recio, I. Antihypertensive peptides: Production, bioavailability and incorporation into foods. Adv Colloid Interface Sci. (2011) 165:23–35. doi: 10.1016/j.cis.2010.11.001
19. Maestri, E, Marmiroli, M, and Marmiroli, N. Bioactive peptides in plant-derived foodstuffs. J Proteome. (2016) 147:140–55. doi: 10.1016/j.jprot.2016.03.048
20. Samtiya, M, Samtiya, S, Badgujar, PC, Puniya, AK, Dhewa, T, and Aluko, RE. Health-promoting and therapeutic attributes of Milk-derived bioactive peptides. Nutrients. (2022) 14:3001. doi: 10.3390/nu14153001
21. Singh, A, Duche, RT, Wandhare, AG, Sian, JK, Singh, BP, Sihag, MK, et al. Milk-derived antimicrobial peptides: overview, applications, and future perspectives. Proteins. (2023) 15:44–62. doi: 10.1007/s12602-022-10004-y
22. Perpetuo, EA, Juliano, L, and Lebrun, I. Biochemical and pharmacological aspects of two Bradykinin-potentiating peptides obtained from Tryptic hydrolysis of casein. J Protein Chem. (2003) 22:601–6. doi: 10.1023/B:JOPC.0000008724.98339.ff
23. Brück, WM, Graverholt, G, and Gibson, GR. A two-stage continuous culture system to study the effect of supplemental α-lactalbumin and glycomacropeptide on mixed cultures of human gut bacteria challenged with enteropathogenic Escherichia coli and Salmonella serotype Typhimurium. J Appl Microbiol. (2003) 95:44–53. doi: 10.1046/j.1365-2672.2003.01959.x
24. Nagaoka, S, Futamura, Y, Miwa, K, Awano, T, Yamauchi, K, Kanamaru, Y, et al. Identification of novel hypocholesterolemic peptides derived from bovine milkβ-lactoglobulin. Biochem Biophys Res Commun. (2001) 281:11–7. doi: 10.1006/bbrc.2001.4298
25. Bu, T, Zheng, J, Liu, L, Li, S, and Wu, J. Milk proteins and their derived peptides on bone health: biological functions, mechanisms, and prospects. Compr Rev Food Sci Food Saf. (2021) 20:2234–62. doi: 10.1111/1541-4337.12707
26. Mohanty, DP, Mohapatra, S, Misra, S, and Sahu, PS. Milk derived bioactive peptides and their impact on human health–a review. Saudi J. Biol. Sci. (2016) 23:577–83. doi: 10.1016/j.sjbs.2015.06.005
27. Goulding, DA, Fox, PF, and O’Mahony, JA. Milk proteins: an overview In: Milk Proteins: From Expression to Food. Cork, Ireland: University College Cork (2019)
28. Aguilar-Toalá, JE, Santiago-López, L, Peres, CM, Peres, C, Garcia, HS, Vallejo-Cordoba, B, et al. Assessment of multifunctional activity of bioactive peptides derived from fermented milk by specific Lactobacillus plantarum strains. J Dairy Sci. (2017) 100:65–75. doi: 10.3168/jds.2016-11846
29. Elfahri, KR, Donkor, ON, and Vasiljevic, T. Potential of novel Lactobacillus helveticus strains and their cell wall bound proteases to release physiologically active peptides from milk proteins. Int Dairy J. (2014) 38:37–46. doi: 10.1016/j.idairyj.2014.03.010
30. Nongonierma, AB, Paolella, S, Mudgil, P, Maqsood, S, and FitzGerald, RJ. Dipeptidyl peptidase IV (DPP-IV) inhibitory properties of camel milk protein hydrolysates generated with trypsin. J Funct Foods. (2017) 34:49–58. doi: 10.1016/j.jff.2017.04.016
31. Nakamura, Y, Yamamoto, N, Sakai, K, Okubo, A, Yamazaki, S, and Takano, T. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour Milk. J Dairy Sci. (1995) 78:1253–7. doi: 10.3168/jds.S0022-0302(95)76689-9
32. Manso, MA, and López-Fandiño, R. Angiotensin I converting enzyme - inhibitory activity of bovine, ovine, and caprine κ-casein macropeptides and their tryptic hydrolysates. J Food Prot. (2003) 66:1686–92. doi: 10.4315/0362-028X-66.9.1686
33. Tu, M, Wang, C, Chen, C, Zhang, R, Liu, H, Lu, W, et al. Identification of a novel ACE-inhibitory peptide from casein and evaluation of the inhibitory mechanisms. Food Chem. (2018) 256:98–104. doi: 10.1016/j.foodchem.2018.02.107
34. Jiang, Z, Tian, B, Brodcrob, A, and Huo, G. Production, analysis and in vivo evaluation of novel angiotensin-I-converting enzyme inhibitory peptides from bovine casein. Food Chem. (2010) 123:779–86. doi: 10.1016/j.foodchem.2010.05.026
35. Uenishi, H, Kabuki, T, Seto, Y, Serizawa, A, and Nakajima, H. Isolation and identification of casein-derived dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats. Int Dairy J. (2012) 22:24–30. doi: 10.1016/j.idairyj.2011.08.002
36. Zheng, L, Xu, Q, Lin, L, Zeng, XA, Sun, B, and Zhao, M. In vitro metabolic stability of a casein-derived Dipeptidyl peptidase-IV (DPP-IV) inhibitory peptide VPYPQ and its controlled release from casein by enzymatic hydrolysis. J Agric Food Chem. (2019) 67:10604–13. doi: 10.1021/acs.jafc.9b03164
37. Rahimi, M, Ghaffari, SM, Salami, M, Mousavy, SJ, Niasari-Naslaji, A, Jahanbani, R, et al. ACE- inhibitory and radical scavenging activities of bioactive peptides obtained from camel milk casein hydrolysis with proteinase K. dairy. Sci Technol. (2016) 96:489–99. doi: 10.1007/s13594-016-0283-4
38. Otte, J, Shalaby, SM, Zakora, M, Pripp, AH, and El-Shabrawy, SA. Angiotensin-converting enzyme inhibitory activity of milk protein hydrolysates: effect of substrate, enzyme and time of hydrolysis. Int Dairy J. (2007) 17:488–503. doi: 10.1016/j.idairyj.2006.05.011
39. Nongonierma, AB, and Fitzgerald, RJ. Dipeptidyl peptidase IV inhibitory and antioxidative properties of milk protein-derived dipeptides and hydrolysates. Peptides. (2013) 39:157–63. doi: 10.1016/j.peptides.2012.11.016
40. Zhang, Y, Chen, R, Zuo, F, Ma, H, Zhang, Y, and Chen, S. Comparison of dipeptidyl peptidase IV-inhibitory activity of peptides from bovine and caprine milk casein by in silico and in vitro analyses. Int Dairy J. (2016) 53:37–44. doi: 10.1016/j.idairyj.2015.10.001
41. Aiello, G, Lammi, C, Boschin, G, Zanoni, C, and Arnoldi, A. Exploration of potentially bioactive peptides generated from the enzymatic hydrolysis of hempseed proteins. J Agric Food Chem. (2017) 65:10174–84. doi: 10.1021/acs.jafc.7b03590
42. Zanoni, C, Aiello, G, Arnoldi, A, and Lammi, C. Hempseed peptides exert Hypocholesterolemic effects with a statin-like mechanism. J Agric Food Chem. (2017) 65:8829–38. doi: 10.1021/acs.jafc.7b02742
43. Howell, S, Kenny, AJ, and Turner, AJ. A survey of membrane peptidases in two human colonic cell lines, Caco-2 and HT-29. Biochem J. (1992) 284:595–601. doi: 10.1042/bj2840595
44. Mentlein, R. Cell-surface peptidases. Int Rev Cytol. (2004) 235:165–213. doi: 10.1016/S0074-7696(04)35004-7
45. Li, Y, Aiello, G, Fassi, EMA, Boschin, G, Bartolomei, M, Bollati, C, et al. Investigation of Chlorella pyrenoidosa protein as a source of novel angiotensin i-converting enzyme (ace) and dipeptidyl peptidase-iv (dpp-iv) inhibitory peptides. Nutrients. (2021) 13:1624. doi: 10.3390/nu13051624
46. Lammi, C, Boschin, G, Bollati, C, Arnoldi, A, Galaverna, G, and Dellafiora, L. A heuristic, computer-driven and top-down approach to identify novel bioactive peptides: a proof-of-principle on angiotensin I converting enzyme inhibitory peptides. Food Res Int. (2021) 150:110753. doi: 10.1016/j.foodres.2021.110753
47. Lammi, C, Bollati, C, Gelain, F, Arnoldi, A, and Pugliese, R. Enhancement of the stability and anti-DPPIV activity of hempseed hydrolysates through self-assembling peptide-based hydrogels. Front Chem. (2019) 6:670. doi: 10.3389/fchem.2018.00670
48. Aiello, G, Li, Y, Boschin, G, Bollati, C, Arnoldi, A, and Lammi, C. Chemical and biological characterization of spirulina protein hydrolysates: focus on ACE and DPP-IV activities modulation. J Funct Foods. (2019) 63:103592. doi: 10.1016/j.jff.2019.103592
49. Li, Y, Aiello, G, Bollati, C, Bartolomei, M, Arnoldi, A, and Lammi, C. Phycobiliproteins from Arthrospira platensis (spirulina): a new source of peptides with dipeptidyl peptidase-IV inhibitory activity. Nutrients. (2020) 12:794. doi: 10.3390/nu12030794
50. Fan, M, Guo, T, Li, W, Chen, J, Li, F, Wang, C, et al. Isolation and identification of novel casein-derived bioactive peptides and potential functions in fermented casein with Lactobacillus helveticus. Food Sci Hum Wellness. (2019) 8:156–76. doi: 10.1016/j.fshw.2019.03.010
51. Boschin, G, Scigliuolo, GM, Resta, D, and Arnoldi, A. Optimization of the enzymatic hydrolysis of lupin (Lupinus) proteins for producing ACE-inhibitory peptides. J Agric Food Chem. (2014) 62:1846–51. doi: 10.1021/jf4039056
52. Boschin, G, Scigliuolo, GM, Resta, D, and Arnoldi, A. ACE-inhibitory activity of enzymatic protein hydrolysates from lupin and other legumes. Food Chem. (2014) 145:34–40. doi: 10.1016/j.foodchem.2013.07.076
53. Lammi, C, Zanoni, C, Ferruzza, S, Ranaldi, G, Sambuy, Y, and Arnoldi, A. Hypocholesterolaemic activity of lupin peptides: investigation on the crosstalk between human enterocytes and hepatocytes using a co-culture system including Caco-2 and HepG2 cells. Nutrients. (2016) 8:437. doi: 10.3390/nu8070437
Keywords: ACE, anti-diabetic property, hypotensive property, casein hydrolysate, DPP-IV
Citation: Li J, Bollati C, Aiello G, Bartolomei M, Rivardo F, Boschin G, Arnoldi A and Lammi C (2023) Evaluation of the multifunctional dipeptidyl-peptidase IV and angiotensin converting enzyme inhibitory properties of a casein hydrolysate using cell-free and cell-based assays. Front. Nutr. 10:1198258. doi: 10.3389/fnut.2023.1198258
Edited by:
Apollinaire Tsopmo, Carleton University, CanadaReviewed by:
Taha Mehany, University of La Rioja, SpainWaseem Khalid, Government College University, Faisalabad, Pakistan
Miryam Amigo-Benavent, University of Limerick, Ireland
Copyright © 2023 Li, Bollati, Aiello, Bartolomei, Rivardo, Boschin, Arnoldi and Lammi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Carmen Lammi, Y2FybWVuLmxhbW1pQHVuaW1pLml0